Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement
Bernard Barlaam, Chris De Savi, Allan Dishington, Lisa Drew, Andrew D. Ferguson, Douglas Ferguson, Chungang Gu, Sudhir M. Hande, Lorraine Hassall, Janet Hawkins, Alexander W. Hird, J. L. Holmes, Michelle L. Lamb, Andrew Lister, Thomas M. McGuire, Jane E. Moore, Nichole O’Connell, Anil S. Patel, Kurt G. Pike, Ujjal Sarkar, Wenlin Shao, Darren Stead, Jeffrey Varnes, Melissa M. Vasbinder, Lei Wang, Liangwei Wu, Lin Xue, Bin Yang, Tieguang Yao
Abstract
Optimization of a series of azabenzimidazoles identified from screening hit 2 and the information gained from a co-crystal structure of the azabenzimidazole-based lead 6 bound to CDK9 led to the discovery of azaindoles as highly potent and selective CDK9 inhibitors. With the goal of discovering a highly selective and potent CDK9 inhibitor administrated intravenously that would enable transient target engagement of CDK9 for the treatment of hematological malignancies, further optimization focusing on physicochemical and pharmacokinetic properties led to azaindoles 38 and 39. These compounds are highly potent and selective CDK9 inhibitors having short half-lives in rodents, suitable physical properties for intravenous administration, and the potential to achieve profound but transient inhibition of CDK9 in vivo.